Aberdeen Group
JANX icon

Aberdeen Group’s Janux Therapeutics JANX Stock Holding History

Aberdeen Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-345,476
Closed -$8.44M – 962
2025
Q3 		$8.44M Buy
345,476
+60,188
+21% +$1.47M 0.01% 635
2025
Q2 		$6.59M Buy
285,288
+60,500
+27% +$1.59M 0.01% 676
2025
Q1 		$6.07M Buy
224,788
+160,716
+251% +$6.06M 0.01% 659
2024
Q4 		$3.43M Buy
+64,072
New +$3.39M 0.01% 702

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Aberdeen Group's JANX Position: Q4 2025 in Review

Aberdeen Group sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 345,476 shares — an estimated $8.44M sold.

Aberdeen Group first reported a position in JANX in Q4 2024 and held it in 4 quarters. The position peaked at $8.44M in Q3 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Aberdeen Group reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Aberdeen Group sold 345,476 Janux Therapeutics shares in Q4 2025, an estimated $8.44M.
  • Aberdeen Group first reported a position in Janux Therapeutics in Q4 2024 and held it in 4 quarters.
  • Aberdeen Group's Janux Therapeutics position peaked at $8.44M in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.